Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus Exenatide

INTRODUCTION: While the liraglutide effect and action in diabetes (LEAD-6) clinical trial compared the efficacy and safety of liraglutide once daily (LIRA) to exenatide twice daily (EXEN) in adult patients with type 2 diabetes, few studies have explored the associated per-patient costs of glycemic g...

Descripción completa

Detalles Bibliográficos
Autores principales: DeKoven, Mitch, Lee, Won Chan, Bouchard, Jonathan, Massoudi, Marjan, Langer, Jakob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930836/
https://www.ncbi.nlm.nih.gov/pubmed/24477354
http://dx.doi.org/10.1007/s12325-014-0098-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930836/
https://www.ncbi.nlm.nih.gov/pubmed/24477354
http://dx.doi.org/10.1007/s12325-014-0098-8

Ejemplares similares